Macrocycles for Drug Discovery
MSCA (Marie Skłodowska-Curie)HORIZON-TMA-MSCA-DNID: 101168916
EC Contribution
€32,708
Consortium Size
20 orgs
Start Year
2024
▶Summary
Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe.New drug modalities such as macrocycles are expected to be a key enabling technology for this strategic perspective. The goal of MC4DD is to train the next generation of European medicinal chemists in a multidisciplinary environment to promote European drug discovery competitiveness, directly by advancing knowhow on macrocycles and long-term via the skills carried on by the researchers trained in the doctoral network.
Consortium (20)
🇩🇪 TECHNISCHE UNIVERSITAT DARMSTADTDE
coordinator🇩🇪 ABBVIE DEUTSCHLAND GMBH & CO KGDE
partner🇩🇪 ANALYTICON DISCOVERY GMBHDE
partner🇸🇪 ASTRAZENECA ABSE
partner🇩🇪 Bayer AGDE
partner🇨🇭 ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNECH
partner🇨🇭 EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICHCH
partner🇩🇪 ENAMINE GERMANY GMBHDE
partner🇨🇭 F. HOFFMANN-LA ROCHE AGCH
partner🇭🇷 FIDELTA DOO ZA ISTRAZIVANJE I RAZVOJHR
partner🇩🇪 JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAINDE
partner🇩🇰 NOVO NORDISK A/SDK
partner🇩🇪 SANOFI-AVENTIS DEUTSCHLAND GMBHDE
partner🇬🇧 THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGEGB
partner🇺🇦 UKRORGSYNTEZ LTDUA
partner🇮🇹 UNIVERSITA DEGLI STUDI DI TORINOIT
partner🇳🇱 UNIVERSITEIT LEIDENNL
partner🇬🇧 UNIVERSITY COLLEGE LONDONGB
partner🇬🇧 UNIVERSITY OF YORKGB
partner🇸🇪 UPPSALA UNIVERSITETSE
partner